Suppr超能文献

首次从日本人类皮肤真菌病中分离出新美棘壳菌。

First Isolation of Neoscytalidium dimidiatum from Human Dermatomycosis in Japan.

机构信息

Department of Dermatology, Kanazawa Medical University.

Ogawa Dermatology Clinic, Sendai.

出版信息

Med Mycol J. 2022;63(3):71-75. doi: 10.3314/mmj.22-00005.

Abstract

Neoscytalidium dimidiatum is a common fungus that causes non-dermatophyte dermatomycosis in tropical regions, but there have been no reports of infection with N. dimidiatum in Japan. Here, we report the first isolation of N. dimidiatum from human dermatomycosis in Japan. A 62-year-old healthy Japanese male had been treated with oral terbinafine for tinea pedis diagnosed from a microscopic examination in 2003 with a lesion that was intractable. In 2020, re-identification by sequencing the internal transcribed spacer regions and the D1/D2 domain of the large-subunit (LSU) ribosomal RNA gene revealed that the pathogen was N. dimidiatum. Antifungal susceptibility tests showed that the minimum inhibitory concentration of the drug luliconazole (LLCZ) against the pathogen was 0.00049 µg/mL. The patient's lesions were cured by topical LLCZ. The clinical course and drug susceptibility suggest that LLCZ is a suitable first-line drug for treatment.

摘要

新斯科细亚假丝酵母是一种常见的真菌,可引起热带地区的非皮肤癣菌性皮肤真菌病,但在日本尚无新斯科细亚假丝酵母感染的报道。在这里,我们报告了首例在日本从人类皮肤真菌病中分离出新斯科细亚假丝酵母的病例。一名 62 岁的健康日本男性曾于 2003 年因足癣(根据显微镜检查诊断)口服特比萘芬治疗,病变一直难以治愈。2020 年,通过对内部转录间隔区和大亚基(LSU)核糖体 RNA 基因的 D1/D2 结构域进行测序重新鉴定,发现病原体为新斯科细亚假丝酵母。抗真菌药敏试验显示,药物卢立康唑(LLCZ)对病原体的最小抑菌浓度为 0.00049 µg/mL。患者的病变通过局部应用 LLCZ 治愈。临床病程和药敏试验提示 LLCZ 是一种合适的一线治疗药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验